PE20231200A1 - Anticuerpos ccr8 para aplicaciones terapeuticas - Google Patents

Anticuerpos ccr8 para aplicaciones terapeuticas

Info

Publication number
PE20231200A1
PE20231200A1 PE2022003003A PE2022003003A PE20231200A1 PE 20231200 A1 PE20231200 A1 PE 20231200A1 PE 2022003003 A PE2022003003 A PE 2022003003A PE 2022003003 A PE2022003003 A PE 2022003003A PE 20231200 A1 PE20231200 A1 PE 20231200A1
Authority
PE
Peru
Prior art keywords
antibodies
methods
human
ccr8
internalizing
Prior art date
Application number
PE2022003003A
Other languages
English (en)
Inventor
Katharina Filarsky
Ahsen Oliver Von
Sandra Berndt
Wiebke Maria Nadler
Philipp Ellinger
Beatrix Stelte-Ludwig
Sabine Hoff
Helge Roider
Ernst Weber
Mark Trautwein
Christian Votsmeier
Nikolaus Pawlowski
Uwe Gritzan
Pascale Buchmann
Christian Bertling
Su-Yi Tseng
Pedro Paz
Phaik Lyn Oh
Patrick Jones
Matyas Gorjanacz
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of PE20231200A1 publication Critical patent/PE20231200A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7158—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for chemokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N2005/1092—Details
    • A61N2005/1098—Enhancing the effect of the particle by an injected agent or implanted device
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invencion se refiere a herramientas y metodos para la generacion de anticuerpos que especificamente se unen a receptores quimiocina, tal como receptores quimiocina CC o CXC. Se proporcionan polipeptidos sulfatados aislados y conjugados de los mismos, que se pueden usar por ejemplo como antigenos o para clasificacion inespecifica para facilitar la generacion de anticuerpos del receptor de quimiocina anti-humanos, anti-cynomolgus, y/o anti-raton, por ejemplo, para la generacion de anticuerpos con CDRs totalmente humanas y/u otras propiedades favorables para uso terapeutico. La presente invencion ademas se refiere a anticuerpos y conjugados de los mismos que pueden obtenerse aplicando las herramientas y metodos antes mencionados. Se proporcionan anticuerpos que especificamente se unen a CCR8 humano, cynomolgus y/o murino con propiedades favorables para uso terapeutico, tal como anticuerpos de reactividad cruzada, anticuerpos totalmente humanos, anticuerpos de internalizacion baja (incluyendo no-internalizacion), y anticuerpos que eficientemente inducen ADCC y/o ADCP en celulas Treg. Biomarcadores, metodos de estratificacion y metodos de diagnostico son finalmente proporcionados para pronosticar o evaluar la capacidad de respuesta a monoterapia de anticuerpo anti- CCR8 o terapia de combinacion.
PE2022003003A 2020-06-26 2021-06-25 Anticuerpos ccr8 para aplicaciones terapeuticas PE20231200A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202062705434P 2020-06-26 2020-06-26
US202062705608P 2020-07-07 2020-07-07
EP20205426 2020-11-03
PCT/EP2021/067504 WO2021152186A2 (en) 2020-06-26 2021-06-25 Ccr8 antibodies for therapeutic applications

Publications (1)

Publication Number Publication Date
PE20231200A1 true PE20231200A1 (es) 2023-08-17

Family

ID=76553783

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2022003003A PE20231200A1 (es) 2020-06-26 2021-06-25 Anticuerpos ccr8 para aplicaciones terapeuticas

Country Status (14)

Country Link
US (3) US20230250178A1 (es)
EP (5) EP4171601A2 (es)
JP (5) JP2023531991A (es)
KR (2) KR20230028780A (es)
CN (6) CN116096395A (es)
AU (2) AU2021295721A1 (es)
BR (2) BR112022026121A2 (es)
CA (3) CA3188146A1 (es)
CL (1) CL2022003747A1 (es)
IL (2) IL298910A (es)
MX (2) MX2022015968A (es)
PE (1) PE20231200A1 (es)
TW (1) TW202216771A (es)
WO (5) WO2021260208A2 (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3169451A1 (en) 2020-02-14 2021-08-19 Jounce Therapeutics, Inc. Antibodies and fusion proteins that bind to ccr8 and uses thereof
CN115052892B (zh) 2020-10-16 2023-07-07 礼新医药科技(上海)有限公司 抗ccr8单克隆抗体及其用途
JPWO2022211046A1 (es) 2021-03-31 2022-10-06
KR20240017912A (ko) * 2021-06-04 2024-02-08 암젠 인크 항-ccr8 항체 및 이의 용도
BR112023024837A2 (pt) 2021-07-27 2024-02-20 Abbvie Inc Anticorpos anti-ccr8
KR20240046533A (ko) * 2021-08-20 2024-04-09 하이파이바이오 인코퍼레이티드 항-ccr8 항체 및 그것의 용도
TW202330504A (zh) 2021-10-28 2023-08-01 美商基利科學股份有限公司 嗒𠯤—３（２ｈ）—酮衍生物
AU2022376954A1 (en) 2021-10-29 2024-05-02 Gilead Sciences, Inc. Cd73 compounds
TW202342533A (zh) * 2021-12-02 2023-11-01 中國大陸商再鼎醫藥（上海）有限公司 Ccr8抗原結合單元及其用途
WO2023122581A2 (en) 2021-12-22 2023-06-29 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
US20230242508A1 (en) 2021-12-22 2023-08-03 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
TW202340168A (zh) 2022-01-28 2023-10-16 美商基利科學股份有限公司 Ｐａｒｐ７抑制劑
EP4245756A1 (en) 2022-03-17 2023-09-20 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
TW202400138A (zh) 2022-04-21 2024-01-01 美商基利科學股份有限公司 Ｋｒａｓ ｇ１２ｄ調節化合物
WO2023230473A1 (en) 2022-05-24 2023-11-30 Bristol-Myers Squibb Company Antibodies that bind to human ccr8
WO2023240135A2 (en) 2022-06-07 2023-12-14 Actinium Pharmaceuticals, Inc. Bifunctional chelators and conjugates
WO2023245074A2 (en) * 2022-06-14 2023-12-21 Purdue Research Foundation Car-expressing pluripotent stem cell-derived neutrophils loaded with drug nanoparticles and uses thereof
WO2024006929A1 (en) 2022-07-01 2024-01-04 Gilead Sciences, Inc. Cd73 compounds
WO2024026400A2 (en) * 2022-07-27 2024-02-01 Varian Medical Systems, Inc. Therapeutic combinations of titr effectors with radiation therapy
WO2024052517A2 (en) * 2022-09-09 2024-03-14 Bayer Aktiengesellschaft Medical use of ccr8 antibodies and dosing schedule
WO2024059909A1 (en) * 2022-09-21 2024-03-28 Monash University Anti-ccr8 antibodies
WO2024062076A1 (en) 2022-09-21 2024-03-28 Domain Therapeutics Anti-ccr8 monoclonal antibodies and their therapeutic use
WO2024062082A1 (en) 2022-09-21 2024-03-28 Domain Therapeutics Anti-ccr8 monoclonal antibodies and their therapeutic use
WO2024062072A2 (en) 2022-09-21 2024-03-28 Domain Therapeutics Anti-ccr8 monoclonal antibodies and their therapeutic use
WO2024077239A1 (en) * 2022-10-07 2024-04-11 Genentech, Inc. Methods of treating cancer with anti-c-c motif chemokine receptor 8 (ccr8) antibodies
WO2024088346A1 (en) * 2022-10-28 2024-05-02 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Anti-ccr8 antibodies and uses thereof
US20240165227A1 (en) * 2022-11-04 2024-05-23 Gilead Sciences, Inc. Anticancer therapies using anti-ccr8 antibody, chemo and immunotherapy combinations
CN117285627A (zh) * 2023-09-06 2023-12-26 百济神州(上海)生物科技有限公司 抗ccr8抗体及其用途

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
EP1690934A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
US6329510B1 (en) * 1999-01-29 2001-12-11 Millennium Pharmaceuticals, Inc. Anti-CCR1 antibodies and methods of use therefor
EP1268554A2 (de) 2000-03-31 2003-01-02 IPF Pharmaceuticals GmbH Diagnostik- und arzneimittel zur untersuchung des zelloberflächenproteoms von tumor- und entzündungszellen sowie zur behandlung von tumorerkrankungen und entzündlichen erkrankungen vorzugsweise mit hilfe einer spezifischen chemokinrezeptor-analyse und der chemokinrezeptor-ligand-interaktion
WO2003096020A2 (en) * 2002-05-13 2003-11-20 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with chemokine receptor 8 (ccr8)
US20080260744A1 (en) * 2002-09-09 2008-10-23 Omeros Corporation G protein coupled receptors and uses thereof
US20050069955A1 (en) * 2003-06-30 2005-03-31 Daniel Plaksin Antibodies and uses thereof
US20050266009A1 (en) * 2003-06-30 2005-12-01 Savient Pharmaceuticals, Inc. Antibodies and uses thereof
US7435596B2 (en) 2004-11-04 2008-10-14 St. Jude Children's Research Hospital, Inc. Modified cell line and method for expansion of NK cell
CA3052445C (en) 2004-07-10 2023-08-22 Kerry S. Campbell Genetically modified human natural killer cell lines
WO2007044756A2 (en) 2005-10-11 2007-04-19 Icos Corporation Monoclonal antibodies recognizing human ccr8
CN101720368A (zh) 2007-03-09 2010-06-02 中国抗体制药有限公司 储备多样性最大化的功能性人化抗体文库之构建及应用
GB0904214D0 (en) * 2009-03-11 2009-04-22 Ucb Pharma Sa Biological products
AR076284A1 (es) 2009-04-29 2011-06-01 Bayer Schering Pharma Ag Inmunoconjugados de antimesotelina y usos de los mismos
JP5746183B2 (ja) 2009-09-22 2015-07-08 プロビオゲン アーゲー 特定のグリカン構造を含有する分子を生成する方法
WO2015148820A1 (en) * 2014-03-27 2015-10-01 Massachusetts Institute Of Technology Water-soluble membrane proteins and methods for the preparation and use thereof
US10087259B1 (en) 2014-04-28 2018-10-02 Memorial Sloan Kettering Cancer Center Depleting tumor-specific tregs
JP6894239B2 (ja) * 2014-05-27 2021-06-30 アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ 増強された抗体の有効性のための普遍的グリコフォームに関する組成物および方法
MA41176A (fr) 2014-12-17 2017-10-24 Bayer As Complexes radio-pharmaceutiques
AU2016305283B2 (en) * 2015-08-10 2022-05-26 Pepmab B.V. Humanized anti-CCR7 receptor antibodies
MA43345A (fr) 2015-10-02 2018-08-08 Hoffmann La Roche Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation
CN109715653A (zh) 2016-05-16 2019-05-03 驰科迈博有限责任公司 肿瘤浸润调节性t细胞中被选择性地去调节的标志物
JP2019519548A (ja) * 2016-06-17 2019-07-11 ヴァリアン メディカル システムズ インコーポレイテッド 放射線処置と組み合わせた免疫調節剤
WO2018112033A1 (en) 2016-12-13 2018-06-21 President And Fellows Of Harvard College Methods and compositions for targeting tumor-infiltrating tregs
CN110573180B (zh) * 2017-03-29 2021-08-17 盐野义制药株式会社 癌症治疗用药物组合物
CA3089754A1 (en) 2018-01-31 2019-08-08 Bayer Aktiengesellschaft Antibody drug conjugates (adcs) with nampt inhibitors
WO2019157098A1 (en) 2018-02-06 2019-08-15 Advaxis, Inc. Compositions comprising a recombinant listeria strain and an anti-ccr8 antibody and methods of use
JP2021527640A (ja) 2018-06-18 2021-10-14 バイエル アクチェンゲゼルシャフトＢａｙｅｒ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 酵素的に切断可能なリンカーおよび改善された活性プロファイルを有する、ｃｘｃｒ５に対して向けられるバインダー／活性薬剤複合体
CN110835374A (zh) * 2018-08-19 2020-02-25 普米斯生物技术(苏州)有限公司 抗ccr8×ctla-4双特异性抗体及其应用
US20210393692A1 (en) 2018-11-13 2021-12-23 Memorial Sloan Kettering Cancer Center Compositions and methods for adoptive cell therapy for cancer
MX2021007576A (es) * 2018-12-27 2021-08-24 Shionogi & Co Nuevo anticuerpo anti receptor 8 de motivo c-c de quimiocina (ccr8).
CN114929278A (zh) * 2020-01-06 2022-08-19 瓦西尼斯公司 抗ccr8抗体及其用途
CA3169451A1 (en) * 2020-02-14 2021-08-19 Jounce Therapeutics, Inc. Antibodies and fusion proteins that bind to ccr8 and uses thereof
CN115551895A (zh) 2020-03-05 2022-12-30 纪念斯隆凯特琳癌症中心 抗ccr8剂
JP2023519254A (ja) 2020-03-23 2023-05-10 ブリストル－マイヤーズ スクイブ カンパニー がんを処置するための抗ｃｃｒ８抗体
JPWO2022004760A1 (es) 2020-06-30 2022-01-06
WO2022003156A1 (en) 2020-07-02 2022-01-06 Oncurious Nv Ccr8 non-blocking binders
WO2022000443A1 (en) 2020-07-03 2022-01-06 Nanjing Immunophage Biotech Co., Ltd. Methods and compositions for targeting tregs using ccr8 inhibitors
US20230320332A1 (en) 2020-09-11 2023-10-12 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Genetically modified non-human animal with human or chimeric ccr8

Also Published As

Publication number Publication date
KR20230028780A (ko) 2023-03-02
CN116096748A (zh) 2023-05-09
JP2023531991A (ja) 2023-07-26
CN117653725A (zh) 2024-03-08
MX2022015954A (es) 2023-01-24
CL2022003747A1 (es) 2023-05-19
KR20230028453A (ko) 2023-02-28
WO2021260209A3 (en) 2022-03-10
MX2022015968A (es) 2023-01-24
EP4171601A2 (en) 2023-05-03
BR112022026208A2 (pt) 2023-01-17
IL298910A (en) 2023-02-01
CN116096750A (zh) 2023-05-09
US11427640B1 (en) 2022-08-30
WO2021260208A3 (en) 2022-03-17
US20230250178A1 (en) 2023-08-10
JP2023531989A (ja) 2023-07-26
US20220363768A1 (en) 2022-11-17
CA3188146A1 (en) 2021-12-30
CN116234825A (zh) 2023-06-06
EP4172202A2 (en) 2023-05-03
WO2021260209A2 (en) 2021-12-30
EP4172204A2 (en) 2023-05-03
AU2021295721A1 (en) 2023-01-19
BR112022026121A2 (pt) 2023-01-17
EP4171602A2 (en) 2023-05-03
CN116096749A (zh) 2023-05-09
EP4172201A2 (en) 2023-05-03
WO2021260208A2 (en) 2021-12-30
WO2021260210A2 (en) 2021-12-30
AU2021212327A1 (en) 2023-01-05
JP2023531988A (ja) 2023-07-26
CA3188142A1 (en) 2021-12-30
JP2023531990A (ja) 2023-07-26
CA3188138A1 (en) 2021-08-05
IL298896A (en) 2023-02-01
WO2021152186A3 (en) 2021-12-02
JP2023531705A (ja) 2023-07-25
WO2021260206A2 (en) 2021-12-30
CN116096395A (zh) 2023-05-09
WO2021152186A2 (en) 2021-08-05
TW202216771A (zh) 2022-05-01
WO2021260210A3 (en) 2022-04-14
WO2021260206A3 (en) 2022-03-17

Similar Documents

Publication Publication Date Title
PE20231200A1 (es) Anticuerpos ccr8 para aplicaciones terapeuticas
DOP2018000212A (es) Moléculas de unión a bcma y métodos de uso de las mismas
CL2012001387A1 (es) Anticuerpos murinos, humanizados o fragmentos de ellos anti-receptor epha2; conjugados citotoxicos; composiciones farmaceuticas que los contienen; secuencias nucleotidicas; vector; celula huesped e hibridomas que los producen y el uso de los anticuerpos en el tratamiento del cancer como en metodos de diagnostico. (divisional de sol. n° 2085-07)
AR110676A1 (es) Tratamiento del cáncer utilizando receptores de antígenos quiméricos
CO2022013525A2 (es) Anticuerpos contra sars-cov-2 y métodos para usarlos
CO2017010190A2 (es) Terapias cd20, terapias cd22 y terapias de combinación con una célula que expresa un receptor quimérico de antígeno (car) de cd19
EA202092945A1 (ru) Различные антигенсвязывающие домены, новые платформы и другие улучшения для клеточной терапии
BR112021016984A2 (pt) Receptores de antígeno quimérico direcionados a dll3 e agentes de ligação
AR063090A1 (es) Proteinas de union al antigeno del receptor de la il-17
CL2016002624A1 (es) Anticuerpos humanos que se unen al gen 3 de activación linfocitaria (lag-3) y los usos de estos (divisional sol. n°0308-2011)
PE20171790A1 (es) Anticuerpos anti-ceacam6 y sus usos
CU20170023A7 (es) Anticuerpos y receptores de antígeno quiméricos específicos para cd19
AR112604A1 (es) Receptores de células t, e inmunoterapia usando los mismos
AR068818A1 (es) Terapia de combinacion con anticuerpos anti-cd20, de tipo i y de tipo ii para el tratamiento del cancer , uso, kit
BR112021019411A2 (pt) Métodos para a produção de células car-nk e uso das mesmas
EA202091982A1 (ru) Химерный антигенный рецептор к рецептору il-13 альфа 2 (il13r2) для опухолеспецифической т-клеточной иммунотерапии
CL2022001554A1 (es) Anticuerpos anti-mertk y métodos de uso de los mismos
BR112022024228A2 (pt) Construtos para receptores de antígeno quiméricos
BR112022009290A2 (pt) Terapia para malignidades de células hematopoiéticas com o uso de células t geneticamente modificadas visando cd70
CL2020001726A1 (es) Anticuerpos monoclonales y métodos para utilizar los mismos.
CO2023009279A2 (es) Moléculas de unión a gucy2c y sus usos
AR112228A1 (es) Molécula de polipéptido con especificidad dual mejorada
CL2021001705A1 (es) Anticuerpos humanizados contra la región de la cadena beta de la 9na familia trbv9 del tcr humano, y sus métodos de uso.
BR112022009611A2 (pt) Anticorpos anti-ror-2 e métodos de uso
AR122763A1 (es) Anticuerpos ccr8 para aplicaciones terapéuticas